Abstract:Drug repositioning, an important method of drug development, is utilized to discover investigational drugs beyond the originally approved indications, expand the application scope of drugs, and reduce the cost of drug development. With the emergence of increasingly drug-disease-related biological networks, the challenge still remains to effectively fuse biological entity data and accurately achieve drug-disease repositioning. This paper proposes a new drug repositioning method named EMPHCN based on enhanced message passing and hypergraph convolutional networks (HGCN). It firstly constructs the homogeneous multi-view information with multiple drug similarity features and then extracts the intra-domain embedding of drugs through the combination of HGCN and channel attention mechanism. Secondly, inter-domain information of known drug-disease associations is extracted by graph convolutional networks combining node and edge embedding (NEEGCN), and a heterogeneous network composed of drugs, proteins and diseases is built as an important auxiliary to enhance the inter-domain message passing of drugs and diseases. Besides, the intra-domain embedding of diseases is also extracted through HGCN. Ultimately, intra-domain and inter-domain embeddings of drugs and diseases are integrated as the final embedding for calculating the drug-disease correlation matrix. Through 10-fold cross-validation on some benchmark datasets, we find that the AUPR of EMPHCN reaches 0.593 (T1) and 0.526 (T2), respectively, and the AUC achieves 0.887 (T1) and 0.961 (T2) respectively, which shows that EMPHCN has an advantage over other state-of-the-art prediction methods. Concerning the new disease association prediction, the AUC of EMPHCN through the five-fold cross-validation reaches 0.806 (T1) and 0.845 (T2), which are 4.3% (T1) and 4.0% (T2) higher than the second best existing methods, respectively. In the case study, EMPHCN also achieves satisfactory results in real drug repositioning for breast carcinoma and Parkinson's disease.

Drug Repurposing Therapeutics Prediction using Hierarchical Graph Neural Network.

Drug repositioning based on the heterogeneous information fusion graph convolutional network

Drug Repositioning Method Based on Deep Neural Network

Uncovering hidden therapeutic indications through drug repurposing with graph neural networks and heterogeneous data

Drug repurposing against breast cancer by integrating drug-exposure expression profiles and drug–drug links based on graph neural network

Drug repositioning based on weighted local information augmented graph neural network

Drug repositioning with adaptive graph convolutional networks

Gndd: A Graph Neural Network-Based Method For Drug-Disease Association Prediction

DRTerHGAT: A Drug Repurposing Method Based on the Ternary Heterogeneous Graph Attention Network

Drug Repositioning Based on the Enhanced Message Passing and Hypergraph Convolutional Networks

HGDD - A Drug-Disease High-Order Association Information Extraction Method for Drug Repurposing via Hypergraph.

Metapath-aggregated heterogeneous graph neural network for drug-target interaction prediction

A foundation model for clinician-centered drug repurposing

REDDA: Integrating multiple biological relations to heterogeneous graph neural network for drug-disease association prediction

Predicting associations between drugs and G protein-coupled receptors using a multi-graph convolutional network

Drug repurposing based on the DTD-GNN graph neural network: revealing the relationships among drugs, targets and diseases

Knowledge-driven drug repurposing using a comprehensive drug knowledge graph

deepDR: a network-based deep learning approach to in silico drug repositioning

Enhancing Drug Repositioning through Local Interactive Learning with Bilinear Attention Networks

KG-Predict: A knowledge graph computational framework for drug repurposing